Program
Axitinib
Also written as “AG-013736”, “axitinib” and “OTX-TKI”.
Its studies are mostly in Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Macular Degeneration · Neoplasms · Carcinoma, led by 6 companies.
Drug pageAxitinib: every studyMany companies study it; this page follows only the 45 they lead. All 139 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 360 open or running | phase 3since May 7, 2007 | Oct 9, 2003 | none ahead |
| Ocular Therapeutixits history only | 54 open or running | phase 3since Jan 12, 2024 | Jun 1, 2018 | Jan 8, 2027phase 3 · NCT06495918 |
| Arog Pharmaceuticalsits history only | 10 open or running | phase 2since Oct 6, 2006 | Oct 6, 2006 | none ahead |
| Merckits history only | 10 open or running | phase 3since Jul 29, 2016 | Jul 29, 2016 | none ahead |
| SFJ Pharma Ltd. IIits history only | 10 open or running | phase 3since May 11, 2012 | May 11, 2012 | none ahead |
| Strata Oncology | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Fortrea, Gilead Sciences and SFJ Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Strata Oncology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 1, 2021First study: phase 2 study in NeoplasmsFirst studyNCT05097599 · 11 enrolled · United States
TargetBeta
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
Studies
The one study Strata Oncology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05097599Neoplasms · United States | 2 | Terminated | Jun 12, 2024 | 11 |
How it is read
Names in the registry
- “AG-013736”, 23 entries
- “axitinib”, 13 entries
- “OTX-TKI”, 8 entries
- “Axitinib (AG-013736)”, 8 entries
- “AG-013736 (axitinib)”, 7 entries
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 8 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Macular Degeneration, 4 studies
- Neoplasms, 3 studies
- Carcinoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.